National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

yttrium Y 90 humanized epratuzumab
A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:90Y-LL2
Y 90 epratuzumab
Y 90 Humanized Monoclonal Antibody LL2
Y 90 monoclonal antibody LL2
Y90 Humanized Epratuzumab
Yttrium Y 90 Humanized Monoclonal Antibody LL2
yttrium Y 90 MOAB LL2
yttrium Y-90 epratuzumab
Abbreviation:Y90 MOAB LL2



Previous:yttrium Y 90 daclizumab, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, yttrium Y 90 DOTA monoclonal antibody HuAFP31, yttrium Y 90 DOTA monoclonal antibody HuPAM4, yttrium Y 90 glass microspheres
Next:yttrium Y 90 ibritumomab tiuxetan, yttrium Y 90 monoclonal antibody B3, yttrium Y 90 monoclonal antibody BrE-3, yttrium Y 90 monoclonal antibody Hu3S193, yttrium Y 90 monoclonal antibody MN-14

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov